Comera Life Sciences Holdings, Inc. (CMRA)

Market Cap	3.07K
Revenue (ttm)	1.00M
Net Income (ttm)	-9.35M
Shares Out	30.74M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,910
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0000 - 0.6900
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About CMRA

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company’s lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 13
• Stock Exchange: OTCMKTS
• Ticker Symbol: CMRA

Financial Performance

In 2022, CMRA's revenue was $633,102, an increase of 97.95% compared to the previous year's $319,832. Losses were -$18.38 million, 237.1% more than in 2021.